Inventiva S.A. (IVA) |
|
6.175 -0.255 (-3.97%)
|
02-03 15:00 |
|
Open: |
6.2495 |
Pre. Close: |
6.43 |
|
High:
|
6.45 |
Low:
|
6.175 |
|
Volume:
|
1,767 |
Market Cap:
|
260(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 3:18:21 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 7.96 One year: 9.3 |
| Support: |
Support1: 5.26 Support2: 4.3 |
| Resistance: |
Resistance1: 6.82 Resistance2: 7.96 |
| Pivot: |
6.17 |
| Moving Average: |
MA(5): 6.09 MA(20): 5.93
MA(100): 4.83 MA(250): 6.91  |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 49.6 %D(3): 54.1 |
| RSI: |
RSI(14): 60.8 |
| 52-week: |
High: 13.65 Low: 3.49 |
| Average Vol(K): |
3-Month: 8 (K) 10-Days: 4 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IVA ] has closed above bottom band by 49.4%. Bollinger Bands are 66.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.46 - 6.5 |
6.5 - 6.54 |
|
Low:
|
6 - 6.04 |
6.04 - 6.08 |
|
Close:
|
6.03 - 6.1 |
6.1 - 6.16 |
|
Company Description |
|
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France. |
Headline News |
Fri, 03 Feb 2023
Iva Sanders Obituary (1933 - 2023) - Legacy.com
Thu, 02 Feb 2023
Iva Smith Obituary (1937 - 2023) - Legacy.com
Wed, 01 Feb 2023
Iva Jean (Wisdom) Smith - WCLU
Wed, 01 Feb 2023
"We Initially Imagined It as a Rectangle That From the Left Starts Off ... - Filmmaker Magazine
Wed, 01 Feb 2023
Iva Morris Obituary (2023) - Legacy.com
Tue, 31 Jan 2023
Arts Society of Kingston welcomes February with performance by Iva Bittová, Timothy Hill, three new exhibitions - The Daily Freeman
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
42 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
23.4 (%) |
|
Shares Short
|
192 (K) |
|
Shares Short P.Month
|
194 (K) |
Stock Financials |
|
EPS
|
-1.34 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.64 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-636.8 |
|
Return on Assets (ttm)
|
-34.4 |
|
Return on Equity (ttm)
|
-70.8 |
|
Qtrly Rev. Growth
|
-11.9 |
|
Gross Profit (p.s.)
|
0.17 |
|
Sales Per Share
|
0.23 |
|
EBITDA (p.s.)
|
-1.46 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-54 (M) |
|
Levered Free Cash Flow
|
-39 (M) |
Stock Valuations |
|
PE Ratio
|
-4.65 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.74 |
|
Price to Sales
|
26.7 |
|
Price to Cash Flow
|
-4.82 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
